-
1
-
-
0037260139
-
Cancer statistics, 2003
-
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
-
(2003)
CA Cancer J Clin
, vol.53
, pp. 5-26
-
-
Jemal, A.1
Murray, T.2
Samuels, A.3
Ghafoor, A.4
Ward, E.5
Thun, M.J.6
-
2
-
-
0030695173
-
Renal cell carcinoma: Recent progress and future directions
-
Mulders P, Figlin R, deKernion JB, et al. Renal cell carcinoma: recent progress and future directions. Cancer Res. 1997;57:5189-5195.
-
(1997)
Cancer Res
, vol.57
, pp. 5189-5195
-
-
Mulders, P.1
Figlin, R.2
DeKernion, J.B.3
-
3
-
-
0029982152
-
Renal cell carcinoma
-
Savage PD. Renal cell carcinoma. Curr Opin Oncol. 1996;8:247-251.
-
(1996)
Curr Opin Oncol
, vol.8
, pp. 247-251
-
-
Savage, P.D.1
-
4
-
-
0035163459
-
Recent advances in kidney cancer and metastatic disease
-
Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int. 2001;68:818-824.
-
(2001)
BJU Int
, vol.68
, pp. 818-824
-
-
Kirkali, Z.1
Tuzel, E.2
Mungan, M.U.3
-
5
-
-
0028929682
-
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
-
Fyfe G, Fisher RI, Rosenberg SA, Sznol A, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
-
(1995)
J Clin Oncol
, vol.13
, pp. 688-696
-
-
Fyfe, G.1
Fisher, R.I.2
Rosenberg, S.A.3
Sznol, A.4
Parkinson, D.R.5
Louie, A.C.6
-
6
-
-
0027944183
-
Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma
-
Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol. 1994;12:2714-2722.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2714-2722
-
-
Guleria, A.S.1
Yang, J.C.2
Topalian, S.L.3
-
7
-
-
0031812910
-
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic disease
-
Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic disease. Cancer. 1998;83:797-805.
-
(1998)
Cancer
, vol.83
, pp. 797-805
-
-
Kammula, U.S.1
White, D.E.2
Rosenberg, S.A.3
-
8
-
-
0027739283
-
Interleukin-2 antitumor and effector cell responses
-
Hawkins MJ. Interleukin-2 antitumor and effector cell responses. Semin Oncol. 1993;20:52-59.
-
(1993)
Semin Oncol
, vol.20
, pp. 52-59
-
-
Hawkins, M.J.1
-
9
-
-
0029947360
-
IL-2 gene therapy of solid tumors: An approach for the prevention of signal transduction defects in T cells
-
Zier KS, Gansbacher B. IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. J Mol Med. 1996;74:127-134.
-
(1996)
J Mol Med
, vol.74
, pp. 127-134
-
-
Zier, K.S.1
Gansbacher, B.2
-
10
-
-
17144451211
-
Plasmid DNA gene therapy: Studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo
-
Parker SE, Khatibi S, Margalith M, et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther. 1996;3:175-185.
-
(1996)
Cancer Gene Ther
, vol.3
, pp. 175-185
-
-
Parker, S.E.1
Khatibi, S.2
Margalith, M.3
-
12
-
-
0032017880
-
Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes
-
Stopeck AT, Hersh EM, Brailey JL, Clark PR, Norman J, Parker SE. Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. Cancer Gene Ther. 1998;5:119-126.
-
(1998)
Cancer Gene Ther
, vol.5
, pp. 119-126
-
-
Stopeck, A.T.1
Hersh, E.M.2
Brailey, J.L.3
Clark, P.R.4
Norman, J.5
Parker, S.E.6
-
13
-
-
0032886544
-
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience
-
Galanis E, Hersh EM, Stopeck AT, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J Clin Oncol. 1999;17:3313-3323.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3313-3323
-
-
Galanis, E.1
Hersh, E.M.2
Stopeck, A.T.3
-
14
-
-
0023013967
-
Immunophenotypic profiles in well-differentiated lymphoproliferative disorders, with emphasis on small lymphocytic lymphoma
-
Spier CM, Crogan TM, Fielder K, et al. Immunophenotypic profiles in well-differentiated lymphoproliferative disorders, with emphasis on small lymphocytic lymphoma. Hum Pathol. 1986;17:1126-1136.
-
(1986)
Hum Pathol
, vol.17
, pp. 1126-1136
-
-
Spier, C.M.1
Crogan, T.M.2
Fielder, K.3
-
15
-
-
0035900808
-
Cancer gene therapy clinical trials: Lessons for the future
-
Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future. Br J Cancer. 2001;85:1432-1436.
-
(2001)
Br J Cancer
, vol.85
, pp. 1432-1436
-
-
Galanis, E.1
Russell, S.2
-
16
-
-
0028978028
-
Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials
-
Horn NA, Meek JA, Budahazi G, et al. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther. 1995;6:565-573.
-
(1995)
Hum Gene Ther
, vol.6
, pp. 565-573
-
-
Horn, N.A.1
Meek, J.A.2
Budahazi, G.3
-
17
-
-
0026813323
-
Karnofsky Memorial Lecture: The immunotherapy and gene therapy of cancer
-
Rosenberg SA. Karnofsky Memorial Lecture: the immunotherapy and gene therapy of cancer. J Clin Oncol. 1992;10:180-199.
-
(1992)
J Clin Oncol
, vol.10
, pp. 180-199
-
-
Rosenberg, S.A.1
-
18
-
-
0030944023
-
Bioactivity of autologous irradiated renal cell carcinoma colony-stimulating factor gene transfer
-
Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma colony-stimulating factor gene transfer. Cancer Res. 1997;57:1537-1546.
-
(1997)
Cancer Res
, vol.57
, pp. 1537-1546
-
-
Simons, J.W.1
Jaffee, E.M.2
Weber, C.E.3
-
19
-
-
8844240935
-
Cancer-modified immunotherapy for renal cell carcinoma
-
Hino O, editor. Basel: Karger
-
Kwai K, Tani K, Asano S, Akaza H. Cancer-modified immunotherapy for renal cell carcinoma. In: Hino O, editor. Kidney cancer: recent results of basic and clinical research. Basel: Karger, 1999:75-81.
-
(1999)
Kidney Cancer: Recent Results of Basic and Clinical Research
, pp. 75-81
-
-
Kwai, K.1
Tani, K.2
Asano, S.3
Akaza, H.4
-
20
-
-
0033765794
-
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
-
Nelson WG, Simons JW, Mikhak BV, et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol. 2000;46:S67-S72.
-
(2000)
Cancer Chemother Pharmacol
, vol.46
-
-
Nelson, W.G.1
Simons, J.W.2
Mikhak, B.V.3
-
21
-
-
0031649098
-
Ex vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology
-
Simons JW, Mikhak B. Ex vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin Oncol. 1998;24:661-676.
-
(1998)
Semin Oncol
, vol.24
, pp. 661-676
-
-
Simons, J.W.1
Mikhak, B.2
-
22
-
-
0030449996
-
Immunotherapy of metastatic renal cell cancer
-
Goey SH, Verweij J, Stoter G. Immunotherapy of metastatic renal cell cancer. Ann Oncol. 1996;7:887-900.
-
(1996)
Ann Oncol
, vol.7
, pp. 887-900
-
-
Goey, S.H.1
Verweij, J.2
Stoter, G.3
-
23
-
-
7144227930
-
Recombinant human interleukin-2, recombinant human interferon-alfa-2a, or both in metastatic renal cell carcinoma
-
Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon-alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med. 1998;338:1272-1278.
-
(1998)
N Engl J Med
, vol.338
, pp. 1272-1278
-
-
Negrier, S.1
Escudier, B.2
Lasset, C.3
-
24
-
-
0033514050
-
Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial
-
Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-17.
-
(1999)
Lancet
, vol.353
, pp. 14-17
-
-
-
25
-
-
0032580508
-
Metastatic renal cell carcinoma: What causes occasional dramatic regressions?
-
Young RC. Metastatic renal cell carcinoma: what causes occasional dramatic regressions? N Engl J Med. 1998;338:1305-1306.
-
(1998)
N Engl J Med
, vol.338
, pp. 1305-1306
-
-
Young, R.C.1
-
26
-
-
0031887379
-
Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?
-
Oliver RT. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now? Br J Cancer. 1998;77:1318-1320.
-
(1998)
Br J Cancer
, vol.77
, pp. 1318-1320
-
-
Oliver, R.T.1
-
27
-
-
0033919797
-
Local cytokine therapy of cancer: Interleukin-2, interferons and related cytokines
-
Bubenik I, Den Otter W, Huland E. Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol Immunother. 2000;49:116-122.
-
(2000)
Cancer Immunol Immunother
, vol.49
, pp. 116-122
-
-
Bubenik, I.1
Den Otter, W.2
Huland, E.3
-
28
-
-
0034660885
-
In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity
-
Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000;60:3832-3837.
-
(2000)
Cancer Res
, vol.60
, pp. 3832-3837
-
-
Egilmez, N.K.1
Jong, Y.S.2
Sabel, M.S.3
Jacob, J.S.4
Mathiowitz, E.5
Bankert, R.B.6
-
29
-
-
0036009005
-
Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma
-
van Herpen CM, De Mulder PH. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2002;41:327-334.
-
(2002)
Crit Rev Oncol Hematol
, vol.41
, pp. 327-334
-
-
Van Herpen, C.M.1
De Mulder, P.H.2
-
30
-
-
0034860187
-
A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy
-
Elias L, Hunt WC. A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy. Oncology. 2001;61:91-101.
-
(2001)
Oncology
, vol.61
, pp. 91-101
-
-
Elias, L.1
Hunt, W.C.2
-
31
-
-
0032772880
-
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
-
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2530-2540
-
-
Motzer, R.J.1
Mazumdar, M.2
Bacik, J.3
Berg, W.4
Amsterdam, A.5
Ferrara, J.6
-
32
-
-
0035816315
-
High density oligonucleotide array analysis of interferon-α2a sensitivity and transcriptional response in melanoma cells
-
Certa U, Seiler M, Padovan E, Spagnoli GC. High density oligonucleotide array analysis of interferon-α2a sensitivity and transcriptional response in melanoma cells. Br J Cancer. 2001;85:107-114.
-
(2001)
Br J Cancer
, vol.85
, pp. 107-114
-
-
Certa, U.1
Seiler, M.2
Padovan, E.3
Spagnoli, G.C.4
|